{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/05/28/3302945/0/en/MiNK-Therapeutics-Announces-First-Patient-Dosed-in-Randomized-Phase-2-Trial-of-agenT-797-in-Acute-Lung-Injury-and-Critical-Illness.html", "message": "News view counter 763670 successfully enlarged"}